134 related articles for article (PubMed ID: 36151048)
1. Improved survival of poor-risk non-seminomatous germ cell tumor patients: real-world data from a single institute in Japan.
Tanuma K; Kawai K; Nitta S; Shiga M; Kawahara T; Negoro H; Onozawa M; Inoue T; Nishiyama H; Miyazaki J
Jpn J Clin Oncol; 2023 Jan; 53(1):74-79. PubMed ID: 36151048
[TBL] [Abstract][Full Text] [Related]
2. Identification of a subgroup with worse prognosis among patients with poor-risk testicular germ cell tumor.
Kojima T; Kawai K; Tsuchiya K; Abe T; Shinohara N; Tanaka T; Masumori N; Yamada S; Arai Y; Narita S; Tsuchiya N; Habuchi T; Nishiyama H
Int J Urol; 2015 Oct; 22(10):923-7. PubMed ID: 26094715
[TBL] [Abstract][Full Text] [Related]
3. Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium.
Bührer E; D'Haese D; Daugaard G; de Wit R; Albany C; Tryakin A; Fizazi K; Stahl O; Gietema JA; De Giorgi U; Cafferty FH; Hansen AR; Tandstad T; Huddart RA; Necchi A; Sweeney CJ; Garcia-Del-Muro X; Heng DYC; Lorch A; Chovanec M; Winquist E; Grimison P; Feldman DR; Terbuch A; Hentrich M; Bokemeyer C; Negaard H; Fankhauser C; Shamash J; Vaughn DJ; Sternberg CN; Heidenreich A; Collette L; Gillessen S; Beyer J
Eur J Cancer; 2024 May; 202():114042. PubMed ID: 38564927
[TBL] [Abstract][Full Text] [Related]
4. Survival of metastatic germ cell cancer patients assessed by international germ cell consensus classification in Japan.
Shintaku I; Satoh M; Okajima E; Fujimoto H; Kamoto T; Ogawa O; Kawai K; Akaza H; Tsukamoto T; Naito S; Miki T; Arai Y
Jpn J Clin Oncol; 2008 Apr; 38(4):281-7. PubMed ID: 18321891
[TBL] [Abstract][Full Text] [Related]
5. Treatment outcome of metastatic testicular cancer at a single institution in Japan, a country with low incidence of germ cell tumor.
Kawai K; Hinotsu S; Oikawa T; Sekido N; Hattori K; Miyanaga N; Hasegawa Y; Kojima H; Shimazui T; Akaza H
Jpn J Clin Oncol; 2006 Nov; 36(11):723-30. PubMed ID: 17082218
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Factors and Treatment Results After Bleomycin, Etoposide, and Cisplatin in Germ Cell Cancer: A Population-based Study.
Kier MG; Lauritsen J; Mortensen MS; Bandak M; Andersen KK; Hansen MK; Agerbaek M; Holm NV; Dalton SO; Johansen C; Daugaard G
Eur Urol; 2017 Feb; 71(2):290-298. PubMed ID: 27649970
[TBL] [Abstract][Full Text] [Related]
7. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
[TBL] [Abstract][Full Text] [Related]
8. A population-based validation of the IGCCCG Update Consortium for survival in metastatic non-seminoma testis cancer.
Incesu RB; Morra S; Scheipner L; Barletta F; Baudo A; Garcia CC; Tappero S; Piccinelli ML; Tian Z; Saad F; Shariat SF; de Cobelli O; Terrone C; Chun FKH; Carmignani L; Briganti A; Ahyai S; Longo N; Tilki D; Graefen M; Karakiewicz PI
Jpn J Clin Oncol; 2024 May; 54(5):592-598. PubMed ID: 38369557
[TBL] [Abstract][Full Text] [Related]
9. Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium.
Gillessen S; Sauvé N; Collette L; Daugaard G; de Wit R; Albany C; Tryakin A; Fizazi K; Stahl O; Gietema JA; De Giorgi U; Cafferty FH; Hansen AR; Tandstad T; Huddart RA; Necchi A; Sweeney CJ; Garcia-Del-Muro X; Heng DYC; Lorch A; Chovanec M; Winquist E; Grimison P; Feldman DR; Terbuch A; Hentrich M; Bokemeyer C; Negaard H; Fankhauser C; Shamash J; Vaughn DJ; Sternberg CN; Heidenreich A; Beyer J;
J Clin Oncol; 2021 May; 39(14):1563-1574. PubMed ID: 33822655
[TBL] [Abstract][Full Text] [Related]
10. Clinical Features and Treatment Outcomes in Patients with Extragonadal Germ Cell Tumors: A Single-center Experience.
Makino T; Konaka H; Namiki M
Anticancer Res; 2016 Jan; 36(1):313-7. PubMed ID: 26722059
[TBL] [Abstract][Full Text] [Related]
11. The management and survival of patients with advanced germ-cell tumours: improving outcome in intermediate and poor prognosis patients.
Bhala N; Coleman JM; Radstone CR; Horsman JM; George J; Hancock BW; Hatton MQ; Coleman RE
Clin Oncol (R Coll Radiol); 2004 Feb; 16(1):40-7. PubMed ID: 14768754
[TBL] [Abstract][Full Text] [Related]
12. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).
Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn-Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Oing C; Bokemeyer C
Urol Oncol; 2019 Nov; 37(11):809.e19-809.e25. PubMed ID: 31494007
[TBL] [Abstract][Full Text] [Related]
13. Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management.
Liu YL; Manning-Geist BL; Knezevic A; Deng L; Bromberg M; Funt SA; Meisel JL; Zivanovic O; Roche KL; Sonoda Y; Gardner GJ; Grisham RN; O'Cearbhaill RE; Tew WP; Abu-Rustum NR; Chi DS; Aghajanian C; Feldman DR
Gynecol Oncol; 2023 Mar; 170():93-101. PubMed ID: 36669327
[TBL] [Abstract][Full Text] [Related]
14. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era.
Sonneveld DJ; Hoekstra HJ; van der Graaf WT; Sluiter WJ; Mulder NH; Willemse PH; Koops HS; Sleijfer DT
Cancer; 2001 Apr; 91(7):1304-15. PubMed ID: 11283931
[TBL] [Abstract][Full Text] [Related]
15. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract][Full Text] [Related]
16. Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors.
Hartmann JT; Nichols CR; Droz JP; Horwich A; Gerl A; Fossa SD; Beyer J; Pont J; Kanz L; Einhorn L; Bokemeyer C
Ann Oncol; 2002 Jul; 13(7):1017-28. PubMed ID: 12176779
[TBL] [Abstract][Full Text] [Related]
17. How to classify, diagnose, treat and follow-up extragonadal germ cell tumors? A systematic review of available evidence.
Winter C; Zengerling F; Busch J; Heinzelbecker J; Pfister D; Ruf C; Lackner J; Albers P; Kliesch S; Schmidt S; Bokemeyer C
World J Urol; 2022 Dec; 40(12):2863-2878. PubMed ID: 35554637
[TBL] [Abstract][Full Text] [Related]
18. Pre-orchiectomy tumor marker levels should not be used for International Germ Cell Consensus Classification (IGCCCG) risk group assignment.
Fankhauser CD; Gerke TA; Roth L; Sander S; Grossmann NC; Kranzbühler B; Eberli D; Sulser T; Beyer J; Hermanns T
J Cancer Res Clin Oncol; 2019 Mar; 145(3):781-785. PubMed ID: 30637464
[TBL] [Abstract][Full Text] [Related]
19. Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: An update based on meta-analysis.
van Dijk MR; Steyerberg EW; Habbema JD
Eur J Cancer; 2006 May; 42(7):820-6. PubMed ID: 16574403
[TBL] [Abstract][Full Text] [Related]
20. Low Survival in Poor Prognosis Metastatic Germ Cell Cancer in Belarus.
Rolevich AI; Borodin DM; Rabcheuski AN; Ivanitskaya TA; Semenov SA; Artsiushkevich LV; Sukalinskaya AV; Zhavrid EA; Krasny SA; Konoplya NE; Polyakov SL
JCO Glob Oncol; 2021 Jan; 7():63-71. PubMed ID: 33434070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
